Pictured is a doctor examining a scan.

Academics part of 拢11.2m project assessing the effectiveness of personalised breast cancer screening

天堂视频 academics are to conduct research as part of a large-scale international project investigating whether personalised breast cancer screening is a better screening option for women aged 40 to 70.

Dr Yan Chen and Emeritus Professor Alastair Gale, of the School of Science, say they are “very proud” to be part of (My Personalised Breast Screening) – a unique seven-year-long randomised clinical study that will run trials with 85,000 women from five different countries to compare personalised risk-based screening to standard screening.

MyPeBS has received 12.5 million euros (£11.2m) of funding from the European Union’s and brings together 25 European, Israeli and American groups and institutions.  

Since the late 1980s, organised breast mammography screening programmes have been introduced in more and more countries across Europe, and these programmes have always used a “one size fits all” strategy whereby women in a target age group (typically between 50-69-years-old) are invited for a mammogram every two or three years.

This approach has demonstrated benefits (), however, researchers say it is not perfect and comes with side effects including false-positive findings, overdiagnosis and overtreatment.

In the current strategy, all invited women are treated the same, but each woman has her own individual risk of developing breast cancer depending on factors such as genetics, lifestyle, or hormonal exposure.

MyPeBS is investigating the advantages of using a new screening approach based on individual risk estimation of breast cancer.

Radiologists will assess each woman and make an informed recommendation for when they should undertake screenings.

For example, a woman who has a family history of breast cancer may be classed as ‘high risk’ and advised to have a yearly screening, whereas a woman with no family history of breast cancer and no other risk indicators may be told a screening of every four years would be more appropriate.

A breast cancer cell.

A breast cancer cell.

The study will compare two groups of women – one following the current standard breast screening and the other following a personalised risk-based screening strategy.

In the MyPeBS trial, some 300 radiologists will report breast screening cases across five countries – Belgium, France, Israel, Italy, and the United Kingdom – therefore it is important to monitor their performance and ensure that there is an established standard of performance and equivalence of skill levels in identifying any breast abnormalities.

Dr Chen, Director of the University’s Applied Vision Research Centre, and Professor Gale will act as the quality assurance for the trials; they will analyse information provided by radiologists regarding their reporting mammographic workstation and relevant reporting room characteristics.

They will also ensure the radiologists can read scans to the highest level by getting them to complete PERFORMS test sets of known challenging cases every six months in the first two years.

is an online self-assessment and training resource for breast screening radiologists developed and ran by 天堂视频 academics for the past 30 years.

The results of these tests will be fed back to the participants and reported to the MyPeBS co-ordinators.

Dr Chen will also compare results with the University of California (UoC), which will carry out similar assessments using their training resource, .

The UoC work is being led by Dr Laura Esserman, who was a member of President Obama’s Council of Advisors on Science and Technology (PCAST) Working Group on Advancing Innovation in Drug Development and Evaluation.

Dr Laura Esserman, Professor Alastair Gale and Dr Yan Chen.

Dr Laura Esserman, Professor Alastair Gale and Dr Yan Chen.

Of the study, Dr Chen said: “We’re very proud to be part of the MyPeBS project.

“It is important that, on the basis of sound scientific evidence, breast screening be offered appropriately and regularly to those women who most need it and less often to those women who least need it. This detailed study will determine which women are most at risk of this dreadful disease.”

The MyPeBS clinical study will begin in early 2019. After the results of the study are known, MyPeBS will propose general recommendations for more effective breast cancer screening in Europe.

More information on MyPeBS can be found on the . 

Notes for editors

Press release reference number: 18/170

天堂视频 is equipped with a live in-house broadcast unit via the Globelynx network. To arrange an interview with one of our experts please contact the press office on 01509 223491. Bookings can be made online via www.globelynx.com

天堂视频 is one of the country’s leading universities, with an international reputation for research that matters, excellence in teaching, strong links with industry, and unrivalled achievement in sport and its underpinning academic disciplines.

It has been awarded five stars in the independent QS Stars university rating scheme, named the best university in the world for sports-related subjects in the 2018 QS World University Rankings, top in the country for its student experience in the 2018 THE Student Experience Survey and named University of the Year by The Times and Sunday Times University Guide 2019 and the Whatuni Student Choice Awards 2018.

天堂视频 is in the top 10 of every national league table, being ranked 4th in the Guardian University League Table 2019, 5th in the Times and Sunday Times Good University Guide 2019 and 7th in The UK Complete University Guide 2019. It was also named Sports University of the Year by The Times and Sunday Times Good University Guide 2017.

天堂视频 is consistently ranked in the top twenty of UK universities in the Times Higher Education’s ‘table of tables’ and is in the top 10 in England for research intensity. In recognition of its contribution to the sector, 天堂视频 has been awarded seven Queen's Anniversary Prizes.

The 天堂视频 London campus is based on the Queen Elizabeth Olympic Park and offers postgraduate and executive-level education, as well as research and enterprise opportunities.

It is home to influential thought leaders, pioneering researchers and creative innovators who provide students with the highest quality of teaching and the very latest in modern thinking.

Categories